PR

Poonam Rai

Active Director Director DIN 08597505
DIN 08597505 First appointment Oct 2019 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2019
Shareholding value •••• Premium profile

About Poonam Rai

Data last updated:

Poonam Rai is a Director at Fidens Pharmaceuticals Private Limited (since 2019). The company operates in Chemicals. Fidens Pharmaceuticals Private Limited reported revenue of ₹49 Lakh (FY 2024).

DIN 08597505
Primary Designation Director
Industry Chemicals
First Appointment 15 Oct 2019
Oldest Company Age 14 yrs
Largest company Fidens Pharmaceuticals Private Limited · ₹49 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director15 Oct 20192012₹49 Lakh (FY 2024)Active

Board colleagues of Poonam Rai

NameDINCompanyDesignation
Atul Kumar Rai05150607Fidens Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Fidens Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Poonam Rai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Poonam Rai

Poonam Rai currently holds 1 directorship: Fidens Pharmaceuticals Private Limited (Director, since 15 Oct 2019, revenue ₹49 Lakh (FY 2024)).

Poonam Rai was first appointed on 15 Oct 2019 as Director at Fidens Pharmaceuticals Private Limited.

The current boards of Poonam Rai's companies include Atul Kumar Rai (Fidens Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available